Ghent University Academic Bibliography

Journal Article
A1
open access

Model-based regional control with anomalous diffusion of multi-drug combined cancer therapy for volume predictions

Clara-Mihaela Ionescu (UGent) and Maria Ghita (UGent)

(2023) SYMMETRY-BASEL. 15(1).

Journal Article
A1
open access

Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives

Kris Cooreman, Bart De Spiegeleer (UGent) , Christof Van Poucke, David Vanavermaete, Daan Delbare, Evelien Wynendaele (UGent) and Bavo De Witte

(2023) ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY. 102.

Add to list

Journal Article
A1
open access

MDACT : a new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs, with an example regimen

Richard E. Kast, Alex Alfieri, I Assi, Hazem, Terry C. Burns, Ashraf M. Elyamany, Maria Gonzalez-Cao, Georg Karpel-Massler, Christine Marosi, Michael E. Salacz, Iacopo Sardi, et al.

(2022) CANCERS. 14(10).

Add to list

Genomic biomarkers to guide precision radiotherapy in prostate cancer

Philip Sutera, Matthew P. Deek, Kim Van der Eecken (UGent) , Alexander W. Wyatt, Amar U. Kishan, Jason K. Molitoris, Matthew J. Ferris, M. Minhaj Siddiqui, Zaker Rana, Mark V. Mishra, et al.

(2022) PROSTATE. 82(Supplement 1). p.S73-S85

Add to list

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Solange Peters, Sarah Danson, Dunson Ejedepang, Urania Dafni, Baktiar Hasan, Hoi-Shen Radcliffe, Frederique Bustin, Jacky Crequit, Linda Coate, Monica Guillot, et al.

(2021) LUNG CANCER. 161. p.76-85

Add to list

Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Matthias Guckenberger, Yolande Lievens (UGent) , Angelique B. Bouma, Laurence Collette, Andre Dekker, Nandita M. deSouza, Anne-Marie C. Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E. Lecouvet, et al.

(2020) LANCET ONCOLOGY. 21(1). p.e18-e28

Add to list

Journal Article
A1
open access

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, et al.

(2020) BMC CANCER. 20(1).

Add to list

Journal Article
A1
open access

Defining oligometastatic disease from a radiation oncology perspective : an ESTRO-ASTRO consensus document

Yolande Lievens (UGent) , Matthias Guckenberger, Daniel Gomez, Morten Hoyer, Puneeth Iyengar, Isabelle Kindts, Alejandra Méndez Romero, Daan Nevens, David Palma, Catherine Park, et al.

(2020) RADIOTHERAPY AND ONCOLOGY. 148. p.157-166

Add to list

Inter-observer variation of hippocampus delineation in hippocampal avoidance prophylactic cranial irradiation

F Bartel, M van Herk, H Vrenken, F Vandaele, S Sunaert, K de Jaeger, NJ Dollekamp, C Carbaat, E Lamers, EMT Dieleman, et al.

(2019) CLINICAL & TRANSLATIONAL ONCOLOGY. 21(2). p.178-186

Add to list

Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC

Fabrice Barlesi, Edward B. Garon, Dong-Wan Kim, Enriqueta Felip, Ji-Youn Han, Joo-Hang Kim, Myung-Ju Ahn, Mary Jo Fidler, Matthew A. Gubens, Jr. de Castro, Gilberto, et al.

(2019) JOURNAL OF THORACIC ONCOLOGY. 14(5). p.793-801

Academic Bibliography

Model-based regional control with anomalous diffusion of multi-drug combined cancer therapy for volume predictions

Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives

MDACT : a new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs, with an example regimen

Genomic biomarkers to guide precision radiotherapy in prostate cancer

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Characterisation and classification of oligometastatic disease : a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial

Defining oligometastatic disease from a radiation oncology perspective : an ESTRO-ASTRO consensus document

Inter-observer variation of hippocampus delineation in hippocampal avoidance prophylactic cranial irradiation

Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC

Contents

Support

Contact